Treatment of refractory pain with botulinum toxins - An evidence-based review

Pain Medicine

Volumn 12, Issue 11, 2011, Pages 1594-1606

  Jabbari, Bahman ^a   Machado, Duarte ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Botulinum toxin A; Botulinum toxin B; Chronic pain; Pain disorder; Pain management; Pain medicine

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; TRIHEXYPHENIDYL; VALPROATE SEMISODIUM;

ADRENERGIC TRANSMISSION; ALLODYNIA; ANALGESIA; BLADDER SPASM; CEREBRAL PALSY; CERVICAL DYSTONIA; CHRONIC DAILY HEADACHE; CHRONIC PAIN; CHRONIC TENSION HEADACHE; DIABETIC NEUROPATHY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; HEMORRHOIDECTOMY; HIP DISLOCATION; HUMAN; INFLUENZA; INJECTION SITE PAIN; IONTOPHORESIS; ISCHIALGIA; KNEE OSTEOARTHRITIS; KNEE PAIN; LIMB WEAKNESS; LOW BACK PAIN; MASTECTOMY; MIGRAINE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYOFASCIAL PAIN; NOCICEPTION; NONHUMAN; PAIN; PELVIS PAIN SYNDROME; PLANTAR FASCIITIS; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; POSTTRAUMATIC PAIN; QUALITY OF LIFE; REFRACTORY PAIN; REVIEW; SENSITIZATION; TENNIS ELBOW; TENSION HEADACHE; TOTAL KNEE REPLACEMENT; TRANSFORMED MIGRAINE; TRIGGER POINT; ULTRASOUND; UNSPECIFIED SIDE EFFECT; VATER PAPILLA STENOSIS; VISUAL ANALOG SCALE; WEAKNESS;

EID: 81855168228     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01245.x     Document Type: Review

References (90)

1. Jankovic J, Albanese A, Atassi Z, etal., eds. Botulinum Toxin: Therapeutic Clinical Practice and Science. New York: Saunders; 2008.
2. Blasi J, Chapman ER, Link E, etal. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-3.
3. Meng J, Ovsepian SV, Wang J, etal. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009;29:4981-92.
4. French J, Gronseth G. Lost in a jungle of evidence: We need a compass. Neurology 2008;71:1634-8.
5. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007;120:2864-74.
6. Lucioni A, Bales GT, Lotan TL, etal. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008;101:366-70.
7. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(suppl 1):S9-15.
8. Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther 2010;334:1080-6.
9. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-33.
10. Namazi H. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: A molecular mechanism. Urology 2008;72:463-4.
11. Chuang YC, Yoshimura N, Huang CC, etal. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008;180:742-8.
12. Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature 1965;206:588-91.
13. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-4.
14. Min-chul S, Watika M, Montomura T, Torri Y, Akaike N. Femtomolar concentrations of A type botulinum toxin inhibit membrane NA channels in rat central and peripheral neurons. Poster # 40 presented to IBRCC meeting in Atlanta-October 2010.
15. Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the NaV1.7 sodium channel. Ann N Y Acad Sci 2010;1184:196-207.
16. Chaddock JA, Purkiss JR, Alexander FC, etal. Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord 2004;19(suppl 8):S42-7.
17. Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol 2010;633:10-4.
18. Gronseth G, French J. Practice parameters and technology assessments: What they are, what they are not, and why you should care. Neurology 2008;71:1639-43.
19. Comella CL. The treatment of cervical dystonia with botulinum toxins. J Neural Transm 2008;115:379-583.
20. Greene P, Kang U, Fahn S, etal. Double-blind, placebo controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-18.
21. Poewe W, Deuschl G, Nebe A, etal. What is the optimum dose of botulinum toxin A in the treatment of cervical dystonia? Result of double-blind, placebo controlled, dose ranging study using Dysport. German dystonia study group. J Neurol Neurosurg Psychiatry 1998;64:13-17.
22. Troung D, Duane DD, Jankovic J, etal. Efficacy and safety of botulinum A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blinded, placebo-controlled study. Mov Disord 2005;20:783-91.
23. Truong D, Brodsky M, Lew M, etal., Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-23.
24. Lew MF, Adornato BT, Duane DD, etal. Botulinum toxin type B: A double-blind, placebo-controlled safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
25. Brin MF, Lew MF, Adler CH, etal. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999;53:1431-8.
26. Brashear A, Lew MF, Dystra DD, etal. Safety and efficacy of Neurobloc (botulinum toxin type B) in type-A responsive cervical dystonia. Neurology 1999;53:1439-46.
27. Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumtoxinB pain associated with cervical dystonia: Results of placebo and comparator-controlled studies. Int J Neurosci 2010;120:298-300.
28. Brans JW, Linderboom R, Snoek JW, etal. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind trial. Neurology 1996;46:1066-72.
29. Comella CL, Jankovic J, Shannon KM, etal., Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-9.
30. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, non-inferiority trial. Mov Disord 2008;23:510-17.
31. Benecke R, Jost WH, Kanovsky P, etal. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-51.
32. Odergren T, Hajaltason H, Kaakola S, etal. A double blind, randomized, parallel group study to investigate the dose equivalance of Dysport and onabotulinum toxin A in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
33. Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type A Botox and Prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 2010;33:27-31.
34. Poewe W, Schelosky L, Kleedorfer B, etal. Treatment of spasmodic torticollis with local injections of botulinum toxin. One year follow up in 37 patients. J Neurol 1992;239:21-5.
35. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety and antibody frequency. German Dystonia Study group. J Neurol 1999;246:265-74.
36. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
37. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008;48:201-9.
38. Aurora SK, Dodick DW, Turkel CC, etal., PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
39. Diener HC, Dodick DW, Aurora SK, etal., PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14.
40. Dodick DW, Turkel CC, DeGryse RE, etal., PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36.
41. Wong SM, Hui AC, Tong PY, etal. Treatment of lateral epicondylitis with botulinum toxin: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2005;143(11):793-7.
42. Hayton MJ, Santini AJ, Hughes PJ, etal. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am 2005;87:503-7.
43. Placzek R, Drescher W, Deuretzbacher G, Hempfing A, Meiss AL. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am 2007;89:255-60.
44. Espandar R, Heidari P, Rasouli MR, etal. Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: A randomized controlled trial. CMAJ 2010;182:768-73.
45. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:S177-81.
46. Xiao L, Mackey S, Hui H, etal. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010;11:1827-33.
47. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-83.
48. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: A short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005;84:649-54.
49. Huang YC, Wei SH, Wang HK, Lieu FK. Ultrasonographic guided botulinum toxin type A treatment for plantar fasciitis: An outcome-based investigation for treating pain and gait changes. J Rehabil Med 2010;42:136-40.
50. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: A pilot study. Am J Phys Med Rehabil 2002;81:751-9.
51. Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil 2002;81:936-42.
52. Brander VA, Stulberg SD, Adams AD, etal. Predicting total knee replacement pain: A prospective, observational study. Clin Orthop Relat Res 2003;416:416-27.
53. Singh JA, Mahowald ML, Noorbaloochi SJ. Intraarticular botulinum toxin a for refractory painful total knee arthroplasty: A randomized controlled trial. J Rheumatol 2010;37:2377-86.
54. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001;56:1290-3.
55. Jabbari B, Ney J, Sichani A, etal. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: An open-label, pilot study. Pain Med 2006;7:260-4.
56. Yuan RY, Sheu JJ, Yu JM, etal. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 2009;72:1473-8.
57. Boon AJ, Smith J, Dahm DL, etal. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: A pilot study. PM R 2010;2:268-76.
58. Singer BJ, Silbert PL, Song S, Dunne JW, Singer KP. Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: A randomised placebo controlled crossover trial. Br J Sports Med 2010;65:640-5.
59. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: A randomized controlled trial. Obstet Gynecol 2006;108:915-23.
60. Barwood S, Baillieu C, Boyd R, etal. Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000;42:116-21.
61. Layeeque R, Hochberg J, Siegel E, etal. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 2004;240:608-13.
62. Davies J, Duffy D, Boyt N, etal. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: Results of a double-blind, randomized study. Dis Colon Rectum 2003;46:1097-102.
63. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: A pilot study. J Rheumatol 2000;27:481-4.
64. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23:1662-6.
65. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type. Anesthesiology 2005;103:377-83.
66. Ojala T, Arokoski JP, Partanen J. The effects of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome. A double blind, randomized, and crossover trial. Clin J Pain 2006;22:90-6.
67. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport Myofascial Pain Study Group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006;125:82-8.
68. Qerama E, Fuglsang-Frederiksen A, Kasch H, Basch FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006;67:241-5.
69. Lew HL, Lee EH, Castaneda A, Kilma R, Date E. Therapeutic doses of botulinum toxin A in treating neck and upper back pain of myofascial origin: A pilot study. Arch Phys Med Rehabil 2008;89:75-80.
70. Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: A randomized, double-blind study. Pain Med 2009;10:1012-17.
71. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5.
72. Mathew NT, Frishberg BM, Gawel M, etal. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized double-blind, placebo-controlled trial. Headache 2005;45:293-307.
73. Dodick DW, Mauskop A, Elkind AH, etal., BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache 2005;45:315-24.
74. Silberstein SD, Stark SR, Lucas SM, etal. Botulinum toxin type a for the prophylactic treatment of chronic daily headache: A randomized, double blind, placebo controlled trial. Mayo Clin Proc 2005;80:1126-37.
75. Naumann M, So Y, Argoff CE, etal. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Neurology 2008;70:1707-14.
76. Harden RN, Cottrill J, Gagnon CM, etal. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: A randomized, double-blind, placebo-controlled pilot study. Headache 2009;49:732-43.
77. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007;8:478-85.
78. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. Pain 2006;7:688-96.
79. Aurora SK, Gawel M, Brandes JL, Pokta S, Vander burgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: A randomized double blind, placebo-controlled exploratory study. Headache 2007;47:486-99.
80. Rejala M, Poole AC, Schoenen J, etal., European BoNTA headache study group. A multi-center randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27:492-503.
81. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-50.
82. Evers S, Vollmer-Haase J, Schwaag S, etal. Botulinum toxin A in the prophylactic treatment of migraine-A randomized, double-blind, placebo-controlled study. Cephalalgia 2004;24:838-43.
83. Vo AH, Satori R, Jabbari B, etal. Botulinum toxin type-a in the prevention of migraine: A double-blind controlled trial. Aviat Space Environ Med 2007;78(suppl 5):B113-18.
84. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20.
85. Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of tension-type headache with botulinum toxin: A double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675-80.
86. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A. A randomized, double blind, placebo-controlled multi-center study. Pain 2004;109:110-14.
87. Silberstein SD, Gobel H, Jensen R, etal. Botulinum toxin type A in the prophylactic treatment of tension-type headache: A multi-center, double blind, randomized, placebo-control, parallel-group study. Cephalalgia 2006;26:790-800.
88. Straube A, Empl M, Ceballos-Baumann A, etal., Dysport Tension-type Headache Study Group. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache-A multi-center, double blind, randomized, placebo-controlled study. Eur J Neurol 2008;15:205-13.
89. Rollnik JD, Tanneberger O, Shubert M, Schnider U, Dengler R. Treatment of tension-type headache with botulinum toxin A: A double-blind, placebo-controlled study. Headache 2000;40:300-5.
90. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of tension-type headaches: A double-blind, placebo-controlled trial. Headache 2001;41:658-64.